Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor

Vittorio Perfetti, Giovanni Palladini, Laura Brunetti, Adele Sgarella, Silvia Brugnatelli, Paolo G. Gobbi, Gino Roberto Corazza

Research output: Contribution to journalArticlepeer-review

Abstract

Bortezomib is the first anticancer proteasome inhibitor introduced into clinical practice. It has been recently approved for the treatment of multiple myeloma, an incurable plasma cell tumour that accounts for 10-15% of all haematologic malignancies and for approximately 20% of deaths. Gastrointestinal toxicity associated with the use of this drug is common but generally mild to moderate. Paralytic ileus in patients undergoing bortezomib treatment has been reported, although a definite attribution to bortezomib administration has not been established. We report a myeloma patient who developed severe paralytic ileus during bortezomib therapy, which presented in the context of progressive constipation without other known causes and which regressed promptly with medical management after drug cessation, suggesting a direct causal relationship. Awareness of the various potential gastrointestinal toxic effects of bortezomib is of relevance given the growing number of patients undergoing treatment with this important and effective new cancer drug.

Original languageEnglish
Pages (from-to)599-601
Number of pages3
JournalEuropean Journal of Gastroenterology and Hepatology
Volume19
Issue number7
DOIs
Publication statusPublished - Jul 2007

Keywords

  • Bortezomib
  • Paralytic ileus
  • Proteasome

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor'. Together they form a unique fingerprint.

Cite this